{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T12:54:21Z","timestamp":1792068861209,"version":"4.4.0"},"reference-count":55,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T00:00:00Z","timestamp":1791417600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001962","name":"World Anti-Doping Agency","doi-asserted-by":"publisher","award":["241A15MT"],"award-info":[{"award-number":["241A15MT"]}],"id":[{"id":"10.13039\/501100001962","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Chromatography B"],"published-print":{"date-parts":[[2026,12]]},"DOI":"10.1016\/j.jchromb.2026.125326","type":"journal-article","created":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T15:30:50Z","timestamp":1791473450000},"page":"125326","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Development and validation of qualitative methods for the detection of GLP-1 receptor agonists in serum and dried blood spots by LC-HRMS\/MS for doping control purposes"],"prefix":"10.1016","volume":"1285","author":[{"given":"Lisa","family":"Borschel","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andreas","family":"Thomas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Studer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Theano","family":"Penlioglou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vissarion","family":"Efthymiou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lia","family":"Bally","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mario","family":"Thevis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jchromb.2026.125326_bb0005","article-title":"Prescribing trends of glucagon-like peptide 1 receptor agonists for type 2 diabetes or obesity","volume":"8","author":"Li","year":"2025","journal-title":"JAMA Netw. Open"},{"key":"10.1016\/j.jchromb.2026.125326_bb0010","doi-asserted-by":"crossref","DOI":"10.1016\/j.peptides.2024.171149","article-title":"Recent advances in peptide-based therapies for obesity and type 2 diabetes","volume":"173","author":"Bailey","year":"2024","journal-title":"Peptides"},{"key":"10.1016\/j.jchromb.2026.125326_bb0015","doi-asserted-by":"crossref","first-page":"1313","DOI":"10.1056\/NEJMra2500106","article-title":"GLP-1 receptor agonists","volume":"394","author":"Rosen","year":"2026","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.jchromb.2026.125326_bb0020","doi-asserted-by":"crossref","first-page":"206","DOI":"10.3803\/EnM.2024.1940","article-title":"Glucagon-like Peptide-1 based therapies: a new horizon in obesity management","volume":"39","author":"Son","year":"2024","journal-title":"Endocrinol Metab (Seoul)"},{"key":"10.1016\/j.jchromb.2026.125326_bb0025","doi-asserted-by":"crossref","first-page":"1772","DOI":"10.1210\/jc.2002-021479","article-title":"Effects of GLP-1-(7-36)NH2, GLP-1-(7-37), and GLP-1- (9-36)NH2 on intravenous glucose tolerance and glucose-induced insulin secretion in healthy humans","volume":"88","author":"Vahl","year":"2003","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"10.1016\/j.jchromb.2026.125326_bb0030","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/j.ejps.2017.03.020","article-title":"Absorption, metabolism and excretion of the GLP-1 analogue semaglutide in humans and nonclinical species","volume":"104","author":"Jensen","year":"2017","journal-title":"Eur. J. Pharm. Sci."},{"key":"10.1016\/j.jchromb.2026.125326_bb0035","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1016\/j.jpba.2018.07.009","article-title":"A liquid chromatography high-resolution mass spectrometry in vitro assay to assess metabolism at the injection site of subcutaneously administered therapeutic peptides","volume":"159","author":"Esposito","year":"2018","journal-title":"J. Pharm. Biomed. Anal."},{"key":"10.1016\/j.jchromb.2026.125326_bb0040","doi-asserted-by":"crossref","first-page":"1944","DOI":"10.1124\/dmd.110.034066","article-title":"Metabolism and excretion of the once-daily human glucagon-like peptide-1 analog liraglutide in healthy male subjects and its in vitro degradation by dipeptidyl peptidase IV and neutral endopeptidase","volume":"38","author":"Malm-Erjefalt","year":"2010","journal-title":"Drug Metab. Dispos."},{"key":"10.1016\/j.jchromb.2026.125326_bb0045","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1016\/j.regpep.2008.07.003","article-title":"Effect of exenatide on gastric emptying and relationship to postprandial glycemia in type 2 diabetes","volume":"151","author":"Linnebjerg","year":"2008","journal-title":"Regul. Pept."},{"key":"10.1016\/j.jchromb.2026.125326_bb0050","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1080\/14656566.2017.1282463","article-title":"Exenatide: pharmacokinetics, clinical use, and future directions","volume":"18","author":"Knop","year":"2017","journal-title":"Expert Opin. Pharmacother."},{"key":"10.1016\/j.jchromb.2026.125326_bb0055","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1310\/hpj5201-65","article-title":"Lixisenatide","volume":"52","author":"Baker","year":"2017","journal-title":"Hosp. Pharm."},{"key":"10.1016\/j.jchromb.2026.125326_bb0060","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1007\/s12325-013-0009-4","article-title":"Mechanisms and clinical efficacy of lixisenatide for the management of type 2 diabetes","volume":"30","author":"Horowitz","year":"2013","journal-title":"Adv. Ther."},{"key":"10.1016\/j.jchromb.2026.125326_bb0065","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejps.2024.106895","article-title":"Absorption, distribution, metabolism, and excretion of tirzepatide in humans, rats, and monkeys","volume":"202","author":"Martin","year":"2024","journal-title":"Eur. J. Pharm. Sci."},{"key":"10.1016\/j.jchromb.2026.125326_bb0070","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1007\/s40262-015-0343-6","article-title":"Liraglutide in type 2 diabetes mellitus: clinical pharmacokinetics and pharmacodynamics","volume":"55","author":"Jacobsen","year":"2016","journal-title":"Clin. Pharmacokinet."},{"key":"10.1016\/j.jchromb.2026.125326_bb0075","doi-asserted-by":"crossref","first-page":"2555","DOI":"10.2147\/DDDT.S470826","article-title":"Clinical pharmacokinetics of Semaglutide: a systematic review","volume":"18","author":"Yang","year":"2024","journal-title":"Drug Des. Devel. Ther."},{"key":"10.1016\/j.jchromb.2026.125326_bb0080","doi-asserted-by":"crossref","DOI":"10.3390\/molecules27134315","article-title":"Tirzepatide, a new era of dual-targeted treatment for diabetes and obesity: a mini-review","volume":"27","author":"Chavda","year":"2022","journal-title":"Molecules"},{"key":"10.1016\/j.jchromb.2026.125326_bb0085","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1111\/dom.14572","article-title":"A phase 1 multiple-ascending dose study of tirzepatide in Japanese participants with type 2 diabetes","volume":"24","author":"Furihata","year":"2022","journal-title":"Diabetes, Obesity and Metabolism"},{"key":"10.1016\/j.jchromb.2026.125326_bb0090","doi-asserted-by":"crossref","DOI":"10.3390\/ijms27146116","article-title":"Incretin-based therapies in sports: pharmacological mechanisms, performance-enhancing potential, and anti-doping implications-a narrative review","volume":"27","author":"La Vignera","year":"2026","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.jchromb.2026.125326_bb0095","doi-asserted-by":"crossref","first-page":"249","DOI":"10.2165\/00007256-199418040-00004","article-title":"Effects of bodyweight reduction on sports performance","volume":"18","author":"Fogelholm","year":"1994","journal-title":"Sports Med."},{"key":"10.1016\/j.jchromb.2026.125326_bb0100","doi-asserted-by":"crossref","first-page":"1148","DOI":"10.1136\/bjsports-2023-106812","article-title":"Best practice recommendations for body composition considerations in sport to reduce health and performance risks: a critical review, original survey and expert opinion by a subgroup of the IOC consensus on relative energy deficiency in sport (REDs)","volume":"57","author":"Mathisen","year":"2023","journal-title":"Br. J. Sports Med."},{"key":"10.1016\/j.jchromb.2026.125326_bb0105","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1002\/oby.24172","article-title":"GLP1Ra-based therapies and DXA-acquired musculoskeletal health outcomes: a focused meta-analysis of placebo-controlled trials","volume":"33","author":"Beavers","year":"2025","journal-title":"Obesity"},{"key":"10.1016\/j.jchromb.2026.125326_bb0110","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1007\/s00592-025-02611-2","article-title":"Muscle loss and GLP-1R agonists use","volume":"63","author":"Rossi","year":"2026","journal-title":"Acta Diabetol."},{"key":"10.1016\/j.jchromb.2026.125326_bb0115","doi-asserted-by":"crossref","unstructured":"K. Prokopidis, S. Cacciatore, S.D. Anton, J.A. Batsis, Risk of protein intake deficiency during treatment with GLP-1 and GIP\/GLP-1 receptor agonists: considerations for secondary sarcopenia, Adv. Ther., Doi: https:\/\/doi.org\/10.1007\/s12325-026-03750-w.","DOI":"10.1007\/s12325-026-03750-w"},{"key":"10.1016\/j.jchromb.2026.125326_bb0120","doi-asserted-by":"crossref","first-page":"1475","DOI":"10.1002\/oby.24336","article-title":"Nutritional priorities to support GLP-1 therapy for obesity: a joint advisory from the American College of Lifestyle Medicine, the American Society for Nutrition, the obesity medicine association, and the Obesity Society","volume":"33","author":"Mozaffarian","year":"2025","journal-title":"Obesity (Silver Spring)"},{"key":"10.1016\/j.jchromb.2026.125326_bb0125","author":"World Anti-Doping Agency"},{"key":"10.1016\/j.jchromb.2026.125326_bb0130","doi-asserted-by":"crossref","DOI":"10.1097\/XCE.0000000000000344","article-title":"Glucagon-like peptide-1 receptor agonists and obesity paradox in heart failure with preserved ejection fraction: a systematic review","volume":"14","author":"Hullon","year":"2025","journal-title":"Cardiovasc Endocrinol Metab."},{"key":"10.1016\/j.jchromb.2026.125326_bb0135","article-title":"Inflammatory biomarker response to GLP-1 receptor agonists versus other glucose-lowering medications in patients with type 2 diabetes: a systematic review and meta-analysis","volume":"16","author":"Alrasheed","year":"2025","journal-title":"Front. Endocrinol. (Lausanne)"},{"key":"10.1016\/j.jchromb.2026.125326_bb0140","doi-asserted-by":"crossref","first-page":"2308","DOI":"10.1093\/eurheartj\/ehaf1066","article-title":"GLP-1R agonists and heart failure: novel beneficial effects suggested by Mendelian randomization","volume":"47","author":"Hu","year":"2026","journal-title":"Eur. Heart J."},{"key":"10.1016\/j.jchromb.2026.125326_bb0145","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1016\/j.coemr.2019.05.004","article-title":"Peptidic drugs and drug candidates in sports drug testing: agents affecting mitochondrial biogenesis or preventing activin receptor II activation","volume":"9","author":"Thevis","year":"2019","journal-title":"Curr. Opinion Endocrine Metabolic Res."},{"key":"10.1016\/j.jchromb.2026.125326_bb0150","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1016\/j.neuroscience.2015.05.023","article-title":"Glucagon-like peptide-1 regulates mitochondrial biogenesis and tau phosphorylation against advanced glycation end product-induced neuronal insult: studies in vivo and in vitro","volume":"300","author":"An","year":"2015","journal-title":"Neuroscience"},{"key":"10.1016\/j.jchromb.2026.125326_bb0155","doi-asserted-by":"crossref","first-page":"1120","DOI":"10.1016\/j.bbrc.2018.11.135","article-title":"Lixisenatide enhances mitochondrial biogenesis and function through regulating the CREB\/PGC-1alpha pathway","volume":"508","author":"Zhao","year":"2019","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"10.1016\/j.jchromb.2026.125326_bb0160","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1038\/d41573-025-00203-x","article-title":"Top product forecasts for 2026","volume":"25","author":"Verdin","year":"2026","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.jchromb.2026.125326_bb0165","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1038\/d41573-026-00041-5","article-title":"Top companies and drugs by sales in 2025","volume":"25","author":"Verdin","year":"2026","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.jchromb.2026.125326_bb0170","author":"World Anti-Doping Agency"},{"key":"10.1016\/j.jchromb.2026.125326_bb0175","author":"World Anti-Doping Agency"},{"key":"10.1016\/j.jchromb.2026.125326_bb0180","author":"World Anti-Doping Agency"},{"key":"10.1016\/j.jchromb.2026.125326_bb0185","doi-asserted-by":"crossref","first-page":"1379","DOI":"10.4155\/bio.11.112","article-title":"Bioanalytical approaches to analyzing peptides and proteins by LC\u2013MS\/MS","volume":"3","author":"Ewles","year":"2011","journal-title":"Bioanalysis"},{"key":"10.1016\/j.jchromb.2026.125326_bb0190","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1016\/j.jpba.2016.03.055","article-title":"Sports drug testing using complementary matrices: advantages and limitations","volume":"130","author":"Thevis","year":"2016","journal-title":"J. Pharm. Biomed. Anal."},{"key":"10.1016\/j.jchromb.2026.125326_bb0195","doi-asserted-by":"crossref","first-page":"1461","DOI":"10.4155\/bio.10.108","article-title":"Application of DBS for quantitative assessment of the peptide Exendin-4; comparison of plasma and DBS method by UHPLC-MS\/MS","volume":"2","author":"Kehler","year":"2010","journal-title":"Bioanalysis"},{"key":"10.1016\/j.jchromb.2026.125326_bb0200","doi-asserted-by":"crossref","first-page":"367","DOI":"10.2174\/138920006776873490","article-title":"Investigation of exenatide elimination and its in vivo and in vitro degradation","volume":"7","author":"Copley","year":"2006","journal-title":"Curr. Drug Metab."},{"key":"10.1016\/j.jchromb.2026.125326_bb0205","author":"European Medicines Agency"},{"key":"10.1016\/j.jchromb.2026.125326_bb0210","author":"World Anti-Doping Agency"},{"key":"10.1016\/j.jchromb.2026.125326_bb0215","doi-asserted-by":"crossref","DOI":"10.1016\/j.ghir.2023.101560","article-title":"A combined top-down and bottom-up LC-HRMS\/MS method for the quantification of human growth hormone in plasma and serum","volume":"72-73","author":"Krombholz","year":"2023","journal-title":"Growth Horm. IGF Res."},{"key":"10.1016\/j.jchromb.2026.125326_bb0220","author":"Cytiva"},{"key":"10.1016\/j.jchromb.2026.125326_bb0225","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1016\/j.ymeth.2011.08.009","article-title":"Immunoaffinity purification of peptide hormones prior to liquid chromatography-mass spectrometry in doping controls","volume":"56","author":"Thomas","year":"2012","journal-title":"Methods"},{"key":"10.1016\/j.jchromb.2026.125326_bb0230","doi-asserted-by":"crossref","first-page":"954","DOI":"10.1124\/pr.115.011395","article-title":"Glucagon-like peptide-1 and its class B G protein-coupled receptors: a long march to therapeutic successes","volume":"68","author":"Graaf","year":"2016","journal-title":"Pharmacol. Rev."},{"key":"10.1016\/j.jchromb.2026.125326_bb0235","doi-asserted-by":"crossref","first-page":"1755","DOI":"10.1002\/dta.2503","article-title":"Recent improvements in sports drug testing concerning the initial testing for peptidic drugs (< 2 kDa) - sample preparation, mass spectrometric detection, and data review","volume":"10","author":"Gorgens","year":"2018","journal-title":"Drug Test. Anal."},{"key":"10.1016\/j.jchromb.2026.125326_bb0240","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1038\/s41366-024-01473-y","article-title":"What is the pipeline for future medications for obesity?","volume":"49","author":"Melson","year":"2025","journal-title":"Int. J. Obes. (Lond)"},{"key":"10.1016\/j.jchromb.2026.125326_bb0245","author":"World Anti-Doping Agency"},{"key":"10.1016\/j.jchromb.2026.125326_bb0250","doi-asserted-by":"crossref","first-page":"556","DOI":"10.1093\/ajcn\/84.3.556","article-title":"Higher fasting plasma concentrations of glucagon-like peptide 1 are associated with higher resting energy expenditure and fat oxidation rates in humans","volume":"84","author":"Pannacciulli","year":"2006","journal-title":"Am. J. Clin. Nutr."},{"key":"10.1016\/j.jchromb.2026.125326_bb0255","doi-asserted-by":"crossref","first-page":"992","DOI":"10.1210\/er.2014-1035","article-title":"Pharmacology, physiology, and mechanisms of action of dipeptidyl peptidase-4 inhibitors","volume":"35","author":"Mulvihill","year":"2014","journal-title":"Endocr. Rev."},{"issue":"Suppl. 1","key":"10.1016\/j.jchromb.2026.125326_bb0260","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1111\/dom.13137","article-title":"Efficacy of glucagon-like peptide-1 receptor agonists compared to dipeptidyl peptidase-4 inhibitors for the management of type 2 diabetes: a meta-analysis of randomized clinical trials","volume":"20","author":"Tran","year":"2018","journal-title":"Diabetes Obes. Metab."},{"key":"10.1016\/j.jchromb.2026.125326_bb0265","doi-asserted-by":"crossref","DOI":"10.1016\/j.jpba.2026.117418","article-title":"In vitro metabolic profiling of weight-loss-inducing amylin receptor agonists in the context of preventive doping research","volume":"273","author":"Alhalabi","year":"2026","journal-title":"J. Pharm. Biomed. Anal."},{"key":"10.1016\/j.jchromb.2026.125326_bb0270","author":"Pfizer"},{"key":"10.1016\/j.jchromb.2026.125326_bb0275","author":"U.S. Food and Drug Administration (FDA)"}],"container-title":["Journal of Chromatography B"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1570023226004150?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1570023226004150?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T12:36:01Z","timestamp":1792067761000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1570023226004150"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,12]]},"references-count":55,"alternative-id":["S1570023226004150"],"URL":"https:\/\/doi.org\/10.1016\/j.jchromb.2026.125326","relation":{},"ISSN":["1570-0232"],"issn-type":[{"value":"1570-0232","type":"print"}],"subject":[],"published":{"date-parts":[[2026,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Development and validation of qualitative methods for the detection of GLP-1 receptor agonists in serum and dried blood spots by LC-HRMS\/MS for doping control purposes","name":"articletitle","label":"Article Title"},{"value":"Journal of Chromatography B","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jchromb.2026.125326","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"125326"}}